| Name | Title | Contact Details |
|---|
MediPharm Labs was created in 2015 by a handful of industry experts in Ontario. With the medicinal benefits of cannabis firmly established – and with a global patient market demanding quality cannabis oil – MediPharm Labs was born. While initially exploring options to cultivate cannabis plant, MediPharm Labs came to recognize the opportunity for a select focus on cannabis concentrates. MediPharm Labs set out to master this area of production, and rely on the many cultivating experts to provide quality raw materials. In 2016, MediPharm labs submitted an application to Health Canada for approval to distribute medicinal cannabis oil. Proudly, MediPharm Labs was one of the first Licensed Producer applications in history to apply for license that did not include the cultivation of cannabis. The key to MediPharm Labs` unrivaled quality is our best possible use of modern technology and innovative extraction techniques. MediPharm Labs produces cannabis oil that is pharmaceutical grade and and meets the specific quality and purity requirements. The team behind MediPharm Labs have proven industry experience in the areas of pharmaceutical extraction, processing and quality assurance. In 2018, MediPharm Labs is gearing up to commence distribution to our Health Canada approved business partners and make history. The response has been enormous, positive and heartening. Medicinal cannabis has arrived – and through our partners we will provide patients with access to pure, consistent and safe cannabis oil. MediPharm Labs commenced construction of a world-class extraction facility in Australia in June 2018. MediPharm Labs Australia is a subsidiary of MediPharm Labs Inc. and the companies` first expansion outside of Canada. MediPharm Labs Australia completed its application process with the federal Office of Drug Control in February 2018 to extract and import medical cannabis products in Australia.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients` lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez`s Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.